TY - JOUR
T1 - New diagnostic measures of oxaliplatin-induced peripheral sensory neuropathy
AU - Szpejewska, Joanna E
AU - Yilmaz, Mette
AU - Falkmer, Ursula G
AU - Arendt-Nielsen, Lars
AU - Mørch, Carsten D
N1 - Centre for Neuroplasticity and Pain (CNAP) is supported by the Danish National Research Foundation (DNRF121)
PY - 2022
Y1 - 2022
N2 - Objective Oxaliplatin-induced peripheral neuropathy (OIPN) is an unwanted side effect of oxaliplatin chemotherapy treatment. OIPN manifests in an acute phase that lasts a few days after injection and a persistent phase that may become chronic. Currently, there is no consensus about a clinically applicable, quantitative, and objective measure of OIPN. Methods Seventeen patients treated with oxaliplatin containing adjuvant chemotherapy for stage III colon cancer, but otherwise healthy, were tested with six quantitative sensory tests (QST) and five large fibre perception threshold tracking (PTT) measures (quantified by, e.g., rheobase and electrotonus threshold) one hour before each of the 12 chemotherapy cycles given at two weeks’ intervals. These measures were repeated at 3, 6, and 12-month follow-ups. The temporal development of OIPN assessed by the Common Terminology Criteria for Adverse Events (CTCAE) scale, QST, and PTT measures was calculated by linear regression. Results The CTCAE score showed a tri-phasic increase during the treatment and remained increased during the follow-up. The vibration threshold (R=0.25, p
AB - Objective Oxaliplatin-induced peripheral neuropathy (OIPN) is an unwanted side effect of oxaliplatin chemotherapy treatment. OIPN manifests in an acute phase that lasts a few days after injection and a persistent phase that may become chronic. Currently, there is no consensus about a clinically applicable, quantitative, and objective measure of OIPN. Methods Seventeen patients treated with oxaliplatin containing adjuvant chemotherapy for stage III colon cancer, but otherwise healthy, were tested with six quantitative sensory tests (QST) and five large fibre perception threshold tracking (PTT) measures (quantified by, e.g., rheobase and electrotonus threshold) one hour before each of the 12 chemotherapy cycles given at two weeks’ intervals. These measures were repeated at 3, 6, and 12-month follow-ups. The temporal development of OIPN assessed by the Common Terminology Criteria for Adverse Events (CTCAE) scale, QST, and PTT measures was calculated by linear regression. Results The CTCAE score showed a tri-phasic increase during the treatment and remained increased during the follow-up. The vibration threshold (R=0.25, p
UR - http://www.scopus.com/inward/record.url?scp=85125619672&partnerID=8YFLogxK
U2 - 10.1016/j.ctarc.2022.100543
DO - 10.1016/j.ctarc.2022.100543
M3 - Journal article
SN - 2468-2942
VL - 31
JO - Cancer Treatment and Research Communications
JF - Cancer Treatment and Research Communications
M1 - 100543
ER -